Press Releases - Intercept Pharmaceuticals, Inc.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Intercept's NASH drug faces its biggest delay yet Jun 29, 2020 NASH - Intercept Pharmaceuticals NASH is usually a silent disease with few or no symptoms. As a result, it can progress for years – or even decades – undetected. As the liver damage becomes more severe, patients with NASH can progress to serious, life-threatening clinical outcomes, including decompensated cirrhosis (in which the liver is permanently damaged and scarred and unable to function properly), end-stage liver ICPT | Intercept Pharmaceuticals Inc. Profile | MarketWatch

May 22, 2020

Intercept Pharmaceuticals - ICPT - Stock Price & News Intercept Pharmaceuticals Shares Fall 13% After FDA Delays an Advisory Committee Meeting Brian Orelli, PhD | May 22, 2020 Investors are feeling more uncertainty about whether obeticholic acid will Intercept: Latest News, Photos, Videos on Intercept - NDTV.COM Jul 13, 2020

Jun 29, 2020

ICPT | Intercept Pharmaceuticals Inc. Profile | MarketWatch